Nagata, Jason M.
Compte, Emilio J.
Cattle, Chloe J.
Lavender, Jason M.
Brown, Tiffany A.
Murray, Stuart B.
Flentje, Annesa
Capriotti, Matthew R.
Lubensky, Micah E.
Obedin-Maliver, Juno
Lunn, Mitchell R.
Article History
Received: 28 January 2021
Accepted: 24 May 2021
First Online: 8 June 2021
Declarations
:
: The University of California, San Francisco (#16–21213) and Stanford University (#48707) Institutional Review Boards approved this study. Written informed consent was obtained from all participants. All study procedures and methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: Dr. Juno Obedin-Maliver has consulted for Sage Therapeutics (5/2017) in a one-day advisory board, Ibis Reproductive Health (a non-for-profit research group; 3/2017–5/2018, 2020-present), Hims Inc. (2019 - present), and Folx, Inc. (2020 – present). Dr. Lunn has consulted for Hims Inc. (2019 - present) and Folx, Inc. (2020). None of these roles present a conflict of interest with this work as described here. The other authors have no conflicts of interest to report.